Literature DB >> 20849330

Dimethylformamide metabolism following self-harm using a veterinary euthanasia product.

Philippe Hantson1, Antoine Villa, Anne-Cécile Galloy, Sara Negri, Giulia Esabon, Fabien Lambiotte, Vincent Haufroid, Robert Garnier.   

Abstract

BACKGROUND: A veterinary euthanasia drug containing embutramide, mebezonium, tetracaine, and dimethylformamide (DMF; T-61® or Tanax®) may cause serious manifestations or even fatalities after self-poisoning. Immediate toxicity is mainly due to a general anesthetic and due to a neuromuscular blocking agent, while delayed hepatotoxicity seems related to the solvent DMF. The protective role of N-acetylcysteine (NAC) administration remains debatable.
MATERIAL AND METHODS: Two male veterinarians (50- and 44-year-old) attempted suicide by injecting T-61 in the precordial area for the first one, and by ingesting 50 mL for the second. Both received NAC (for 14 days in the first case and only for 20 h in the second). Urine was collected for the serial determination of DMF, N-methylformamide (NMF), and N-acetyl-S-(N-methylcarbamoyl)cysteine (AMCC).
RESULTS: Both patients developed only mild signs of liver injury. The metabolite of DMF, NMF, appeared rapidly in the urine, while a further delay was necessary for AMCC excretion. The kinetics of elimination of DMF and DMF metabolites were slightly slower than those reported in exposed workers.
CONCLUSIONS: While both patients had a favorable outcome, there is no clear evidence that NAC could directly influence NMF and AMCC excretion. Further investigations of NMF and AMCC excretion, with and without NAC, would be indicated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20849330     DOI: 10.3109/15563650.2010.498790

Source DB:  PubMed          Journal:  Clin Toxicol (Phila)        ISSN: 1556-3650            Impact factor:   4.467


  1 in total

1.  Clinical outcomes of occupational exposure to n,n-dimethylformamide: perspectives from experimental toxicology.

Authors:  Tae Hyun Kim; Sang Geon Kim
Journal:  Saf Health Work       Date:  2011-06-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.